Evaluation of the new generation of conjugate vaccines is hampered by the absence of reliable surrogate markers of immunologic memory. Memory responses are characterized by rapid production of relatively high-avidity antibody; thus, a solid-phase ELISA was adapted for the measurement of anti -Haemophilus influenzae type b (Hib) IgG avidity. In a cohort of infants vaccinated at 2, 3, and 4 months of age with Hib conjugate vaccines, avidity increased in the period following vaccination, while antibody titer fell. After a booster dose at 1 year of age, both antibody titer and avidity increased. In a cohort with anti-Hib IgG õ1.0 mg/mL following primary immunization, antibody avidity after booster was low, indicating an absence of priming. Antibody avidity may help distinguish, in persons with low antibody titers, between those who are primed for memory and those who are not.
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New-generation bacterial conjugate vaccines are currently
Antibody avidity, the strength with which an antibody binds to an antigen, increases over time following encounter with an in accelerated development following the dramatic success of the Haemophilus influenzae type b (Hib) conjugate vaccines in antigen. Memory responses are characterized by the production of high-avidity antibody; thus, avidity could be considered a reducing the incidence of invasive Hib disease [1] . The success of such vaccines is due to the chemical conjugation of the surrogate of successful priming. Recent advances in the measurement of antibody avidity permit the application of such capsular polysaccharide to a carrier protein, thereby rendering the carbohydrate component immunogenic, even in very young measurements to large numbers of sera, such as those obtained during a vaccine trial [3] . children. In addition to their immunogenicity, the vaccines also appear to prime for memory responses, which is crucial if the We have developed an assay for the measurement of anti-PRP antibody avidity and have evaluated sera obtained from vaccine is to provide long-lasting immunity. Evaluation of Hib conjugate vaccine immunogenicity relies on the measurement infants who have undergone primary immunization with Hib conjugate vaccines and received a booster dose at 1 year of of serum antibody titers to Hib capsular polysaccharide (polyriage. We have measured both titer and avidity of Hib-specific bosylribitol phosphate [PRP] ) and the interpretation of the titer IgG after primary immunization, before booster, and after in the light of the accepted levels for short-term (ú0.15 mg/ booster immunization to assess whether antibody avidity may mL) or long-term (ú1.0 mg/mL) protection [2] . These levels, provide a surrogate marker of successful priming following however, were derived by passive immunization or immunizaprimary immunization. tion with pure polysaccharides; thus, their relevance for protection in children who have been primed for memory responses remains unclear. Ideally, therefore, the evaluation of vaccine immunogenicity should incorporate a surrogate marker of primMethods ing.
This study is a follow-up of a previously reported study in which we assessed the interchangeability of two different Hib conjugate vaccines given according to the United Kingdom accelerated immunization schedule [4] . We enrolled infants aged 8-12 weeks When the postbooster avidity indices of individual vaccinees previously described by us [3, 7] and modified for the Hib assay.
in whom data on antibody titer were available at all time points
Briefly, sera were diluted in PBS-0.05% Tween 20-1% bovine were stratified according to their antibody titer after primary serum albumin (PBS-T-BSA) to a final concentration of Ç0.5 mg/mL (minimum dilution, 1:4) and were then allowed to bind for immunization, differences were noted. Subjects with an anti-2 h at room temperature to an antigen-coated plate. After washing, body titer õ1.0 mg/mL at 5 months of age had significantly ammonium thiocyanate diluted in PBS-T-BSA was added in dulower GMAIs after boosting than did vaccinees who mounted plicate at concentrations of 0-1 M. After 15 min at room temperaa long-term protective response after primary immunization ture, the wells were washed, and antibody binding was then de- (table 1 ). In addition, the antibody response of this group after tected by the addition of a mouse anti-human IgG (R10;
boosting was significantly lower than that of the subjects who the effect seen when the subjects are stratified according to Antibody avidity was displayed as an avidity index corresponding their initial response is a threshold effect.
to the molar concentration of ammonium thiocyanate required to
Responses to the two conjugate formulations used for boostproduce a 50% reduction in absorbance [3] .
ing were compared. The GMT of anti-PRP IgG for the group were positively skewed and thus log-transformed before analysis.
P Å .004) for those boosted with HbOC. Despite the difference Geometric mean titers were compared between the groups by twosample Student's t tests.
Results
As previously reported, 512 infants were analyzed before and after primary immunization. The geometric mean titer (GMT) of anti-PRP IgG for the entire cohort 1 month following primary immunization was 6.23 mg/mL (95% confidence interval [CI], 6.15 -6.30), with 92.4% achieving an antibody titer ú1.0 mg/mL [4]. Paired sera from 376 infants were available for analysis before and after boosting. At 1 year of age, the GMT of anti-PRP IgG had fallen to 0.40 (95% CI, 0.34 -0.47) for all vaccinees; 38.8% had antibody titers below the shortterm protective titer of 0.15 mg/mL and only 31.9% had antibody titers ú1.0 mg/mL. After booster immunization at 1 year of age, antibody titer increased significantly for all vaccinees (GMT, 113.92; 95% CI, 97.4 -133.2).
The geometric mean avidity index (GMAI) for all vaccinees at 5 months of age following three doses of Hib conjugate NOTE. Data are mg/mL for GMTs. Data in parentheses are 95% confidence interval. PRP, Hib capsular polysaccharide. Suboptimal responses were defined as anti-PRP IgG titers õ1.0 mg/mL 1 month after third dose of Hib conjugate vaccine. Differences in antibody levels were compared by 2-sample Student's t test.
in antibody titer for recipients of the two conjugates, no differble that further increases in avidity may take place in the months after the booster dose. ence was noted in the GMAI after boosting. Recipients of a PRP-T booster had a GMAI of 0.52 (95% CI, 0.46 -0.57),
In a small subgroup of subjects with suboptimal primary compared with a GMAI of 0.53 (95% CI, 0.49 -0.58) for the responses, the avidity after boosting was low and the same as recipients of an HbOC booster (P Å .60).
that seen after primary immunization. The suggestion that these subjects had not been adequately primed and thus were mounting a primary response at 1 year of age was reinforced by the Discussion lower GMT of anti-PRP IgG achieved after boosting, a titer comparable to that achieved by older children after a single Surrogate markers of priming are relevant to an understanddose of Hib conjugate [11] . It will be interesting to see whether ing of the immunologic basis of protection afforded by the newthese subjects show increase in antibody avidity over time after generation bacterial conjugate vaccines. Theoretically, persons this booster dose. With increased sensitivity of the assay, it with low or undetectable specific IgG titers will be protected will be possible to measure the antibody avidity of low-titer from infection if they are primed for memory responses, as serum. This will permit studies of naturally occurring anti-PRP they are able to rapidly produce specific IgG of relatively high
IgG antibodies and an analysis of changes in antibody avidity avidity on encounter with the relevant antigen. Thus, in persons with increasing age as well as the study of vaccine failure. with low titers of antibody, measures of antibody avidity may Previous reports of higher antibodies being induced by be able to discriminate between those successfully primed in booster doses of PRP-T compared with other Hib conjugate infancy, who may be considered to be protected, and those formulations [12, 13] were confirmed in our study. Despite the with low-avidity antibody, who may technically be at risk of higher anti-PRP IgG titers after boosting with PRP-T, the invasive Hib disease. Evidence of the superiority of high-com-GMAI was similar for the two vaccines. These data support pared with low-avidity antibody in its ability to kill Haemophithose of Agbarakwe et al. [14] , who analyzed antibody avidity lus influenzae type b in vitro has been shown [8] .
by means of a urea elution assay and found no difference in The strict requirements for the measurement of ''true'' antithe avidity of antibodies induced by primary immunization of body affinity (monoclonal sources of antibody, highly purified infants with PRP-T, HbOC, or PRP conjugated to outer memhaptenic antigens) have precluded the widespread use of such brane proteins (PRP-OMP). In contrast, in a study using a assays in the assessment of vaccine responses. Our approach radioantigen-binding technique for the measurement of avidity, has been to adapt solid-phase assays developed for the measureantibodies induced by primary immunization with HbOC were ment of antibody titer to measure antibody avidity. Avidity, shown to be of higher avidity than those induced by PRP-T defined as the bivalent interaction of antibody with complex and PRP-OMP [15] . antigens, is, we believe, more closely analogous to the complex Currently, antibody titer alone is the sole measure of vaccine interaction encountered in vivo and thus a more relevant bioimmunogenicity, and while such measurements may adelogic measurement than is affinity. We, and others, have valiquately reflect the immediate response to a vaccine, they cannot dated the thiocyanate elution assays by comparison with equibe relied on to reflect immune status months or years after the librium dialysis as well as with biospecific interaction, analysis immunization with a vaccine that induces memory. Current [9, 10] .
concern surrounding the reduced immunogenicity of combinaIn this study, we have shown that antibody avidity is relation vaccines containing acellular pertussis and Hib conjugate tively low following primary immunization and significantly in the same formulation [16] highlight the urgent need for an higher following boosting. The majority of the increase in avidimproved understanding of the relationship between primary ity was seen in the months after primary immunization, and boosting only slightly increased the avidity further. It is possiantibody responses and long-term protection. Reduced anti-/ 9d43$$ap48 03-04-98 19:03:33 jinfa UC: J Infect
